SMMT

Summit Therapeutics Inc. (SMMT) | Rumor.io

Summit Therapeutics

SMMT

Attention (50-day avg)0.01%

Attention rank (50-day avg)#491

Bullish sentiment (50-day avg)87%

Price to earnings ratio25

Market capitalization12.3B

Earnings per share-1.11

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-1.1B

Social

What share of all stock conversation is about SMMT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.05% -0.04	0.02% +0.01	0.01% +0.01	0% -0.01

Sep 29

$SMMT's stock price has been raised by Citi from $40 to $43 following AstraZeneca's $2 billion strategic investment.
AstraZeneca's investment in $SMMT shows the company's confidence in Summit Therapeutics' upcoming FDA approval, with some analysts predicting a stock price drop to sub $10 if approval is denied.
The board of AstraZeneca has undergone intense scrutiny in due diligence for the investment, indicating the company's thorough review of $SMMT's data and operations.

Generated by AI

Sentiment

Of the messages about SMMT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	84.06% +1.45	84.64% -13.65	89.34% +6.7	87.57% +16.12
Bearish	15.94% -1.45	15.36% +13.65	10.66% -6.7	12.43% -16.12

Bullish· Sep 29

AstraZeneca's $2 billion strategic investment in Summit Therapeutics (SMMT) is a significant vote of confidence in the company's prospects, with the board of directors having access to all its data and financials.
Analyst Citi has raised its price target for SMMT from $40 to $43, following the announcement of AstraZeneca's investment, indicating increased optimism about the company's future.
The stock is experiencing a short squeeze, with the shorts working hard to cover, and the author believes the stock will continue to move up, with the potential to test $18-19 and eventually $20-22 with FDA approval in November.

Bearish· Sep 29

The company's stock price struggles to hold above $16 despite a $2 billion investment from a major pharma company.
The market appears to be manipulated, with the stock being dumped at the open and lacking confidence from investors.
The stock's price is being held back by the company's poor performance, with all great news failing to push the stock above $40.

Generated by AI

Topics

Of the messages about SMMT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	25%	65.56%	43.56%	57.6%
Technical Analysis	0.64%	1.38%	22.29%	8.31%
Analysts	42.31%	19.28%	12.94%	15.3%
Earnings	0%	0%	0.19%	9.03%
Controversies	0%	0%	0%	0.83%
Macro	32.05%	13.77%	21.01%	8.93%

Announcements· Sep 29

AstraZeneca has invested $2 billion in Summit Therapeutics, the largest investment in the company's history, and will hold a 12% stake in the company.
The investment is part of a clinical collaboration to accelerate the development of ivonescimab, a cancer treatment drug, and will be used to test the drug in combination with AstraZeneca's cancer medicines.
The investment is a significant validation of ivonescimab's potential and has the potential to be a major catalyst for the company, with upcoming high-profile presentations at ESMO and an FDA PDUFA decision on November 14.

Technical Analysis· Sep 13

$SMMT has broken out of a bull flag and is expected to continue its upward trend.
The stock's RSI is at 88.41, indicating it may be overbought, and recent gaps need to be closed.
The key level to test is $32-$34, with a key support zone at $22.7-$23.4.

Generated by AI

Community

Of the messages about SMMT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	42.76%	52.83%	59.89%	64.65%
Newcomers	57.24%	47.17%	40.11%	35.35%

Regulars· Sep 29

The recent $2 billion investment by AstraZeneca is a strong vote of confidence in Summit Therapeutics' Ivonescimab, indicating a high chance of FDA approval.
The amount of scrutiny the AZN board had to undergo during due diligence on SMMT is a testament to the potential of Ivonescimab, and the company's ability to deliver on its promises.
The recent surge in trading volume and price, combined with the confidence of AZN's investment, suggests that SMMT is poised for a significant gain, potentially reaching $22.55.

Newcomers· Sep 29

Newcomers are optimistic about Summit Therapeutics (SMMT) after AstraZeneca's $2 billion strategic investment, with some expecting significant price increases.
Several posts mention AstraZeneca's price of $18.37 per share and speculate that SMMT will eventually reach or exceed this price.
There is a mix of cautious and enthusiastic reactions to SMMT's recent price movements, with some users predicting a squeeze or expecting the stock to close at a higher price.

Generated by AI

News

A $2 Billion Reason Why AstraZeneca Stock Is Down Today

16h agoYahoo Finance

AstraZeneca's $2 Billion Investment in Summit Therapeutics Seen as 'Win-Win,' UBS Says

AstraZeneca's (AZN) $2 billion investment in Summit Therapeutics (SMMT) is a "win-win" and potential

17h agoYahoo Finance

Summit Therapeutics: Stronger Balance Sheet Helps, But It Does Not De-Risk Ivonescimab

19h agoSeeking Alpha

AstraZeneca Stock Slips as $2 Billion Summit Stake Deepens Oncology

19h agoYahoo Finance

Summit Stock Jumps 17% on $2 Billion AstraZeneca Investment

20h agoYahoo Finance

Summit Shares Jump on $2B Strategic Investment From AstraZeneca

SMMT shares jump as AstraZeneca commits $2 billion to accelerate ivonescimab development and expand clinical collaboration.

20h agoYahoo Finance Australia

Also Discussed

Investors talking about SMMT also mention

#	Name	Attention
1	Pharvaris N.V. Ordinary SharesPHVS	0%0
2	Pulse Biosciences IncPLSE	0%+0
3	Instil Bio Inc.TIL	0%0
4	Revolution Medicines, Inc.RVMD	0.01%-0.01
5	AMAM - Ambrx Biopharma Inc.	——
6	Replimune Group, Inc.REPL	0%0
7	BeOne Medicines Ltd. American Depositary SharesONC	0%0
8	Nuvalent, Inc.NUVL	0%0
9	Mineralys Therapeutics, Inc.MLYS	0%+0
10	Vera Therapeutics Inc.VERA	0%new

Summit Therapeutics Inc.

Healthcare
Biotechnology

Summit Therapeutics Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing therapies for serious unmet medical needs. Summit Therapeutics Inc. centers its current portfolio on oncology, with ivonescimab as its lead investigational asset, a bispecific antibody designed to combine immune checkpoint blockade with anti-angiogenic activity. The company is advancing ivonescimab in multiple late-stage clinical programs for non-small cell lung cancer and colorectal cancer, often in combination with chemotherapy. Summit Therapeutics Inc. also maintains an anti-infectives program, including ridinilazole, an oral antibiotic candidate studied for Clostridioides difficile infection. Through these product and development efforts, Summit Therapeutics Inc. plays a role in precision medicine across cancer and infectious disease, with a focus on therapies intended to address difficult-to-treat conditions.

Website

Location

601 Brickell Key Drive

Miami, FL, 33131

United States

Social

What share of all stock conversation is about SMMT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.05% -0.04	0.02% +0.01	0.01% +0.01	0% -0.01

Sep 29

$SMMT's stock price has been raised by Citi from $40 to $43 following AstraZeneca's $2 billion strategic investment.
AstraZeneca's investment in $SMMT shows the company's confidence in Summit Therapeutics' upcoming FDA approval, with some analysts predicting a stock price drop to sub $10 if approval is denied.
The board of AstraZeneca has undergone intense scrutiny in due diligence for the investment, indicating the company's thorough review of $SMMT's data and operations.

Generated by AI

Sentiment

Of the messages about SMMT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	84.06% +1.45	84.64% -13.65	89.34% +6.7	87.57% +16.12
Bearish	15.94% -1.45	15.36% +13.65	10.66% -6.7	12.43% -16.12

Bullish· Sep 29

AstraZeneca's $2 billion strategic investment in Summit Therapeutics (SMMT) is a significant vote of confidence in the company's prospects, with the board of directors having access to all its data and financials.
Analyst Citi has raised its price target for SMMT from $40 to $43, following the announcement of AstraZeneca's investment, indicating increased optimism about the company's future.
The stock is experiencing a short squeeze, with the shorts working hard to cover, and the author believes the stock will continue to move up, with the potential to test $18-19 and eventually $20-22 with FDA approval in November.

Bearish· Sep 29

The company's stock price struggles to hold above $16 despite a $2 billion investment from a major pharma company.
The market appears to be manipulated, with the stock being dumped at the open and lacking confidence from investors.
The stock's price is being held back by the company's poor performance, with all great news failing to push the stock above $40.

Generated by AI

Topics

Of the messages about SMMT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	25%	65.56%	43.56%	57.6%
Technical Analysis	0.64%	1.38%	22.29%	8.31%
Analysts	42.31%	19.28%	12.94%	15.3%
Earnings	0%	0%	0.19%	9.03%
Controversies	0%	0%	0%	0.83%
Macro	32.05%	13.77%	21.01%	8.93%

Announcements· Sep 29

AstraZeneca has invested $2 billion in Summit Therapeutics, the largest investment in the company's history, and will hold a 12% stake in the company.
The investment is part of a clinical collaboration to accelerate the development of ivonescimab, a cancer treatment drug, and will be used to test the drug in combination with AstraZeneca's cancer medicines.
The investment is a significant validation of ivonescimab's potential and has the potential to be a major catalyst for the company, with upcoming high-profile presentations at ESMO and an FDA PDUFA decision on November 14.

Technical Analysis· Sep 13

$SMMT has broken out of a bull flag and is expected to continue its upward trend.
The stock's RSI is at 88.41, indicating it may be overbought, and recent gaps need to be closed.
The key level to test is $32-$34, with a key support zone at $22.7-$23.4.

Generated by AI

Community

Of the messages about SMMT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	42.76%	52.83%	59.89%	64.65%
Newcomers	57.24%	47.17%	40.11%	35.35%

Regulars· Sep 29

The recent $2 billion investment by AstraZeneca is a strong vote of confidence in Summit Therapeutics' Ivonescimab, indicating a high chance of FDA approval.
The amount of scrutiny the AZN board had to undergo during due diligence on SMMT is a testament to the potential of Ivonescimab, and the company's ability to deliver on its promises.
The recent surge in trading volume and price, combined with the confidence of AZN's investment, suggests that SMMT is poised for a significant gain, potentially reaching $22.55.

Newcomers· Sep 29

Newcomers are optimistic about Summit Therapeutics (SMMT) after AstraZeneca's $2 billion strategic investment, with some expecting significant price increases.
Several posts mention AstraZeneca's price of $18.37 per share and speculate that SMMT will eventually reach or exceed this price.
There is a mix of cautious and enthusiastic reactions to SMMT's recent price movements, with some users predicting a squeeze or expecting the stock to close at a higher price.

Generated by AI

Summit Therapeutics

Social

Sep 29

Bullish· Sep 29

Bearish· Sep 29

Announcements· Sep 29

Technical Analysis· Sep 13

Regulars· Sep 29

Newcomers· Sep 29

A $2 Billion Reason Why AstraZeneca Stock Is Down Today

AstraZeneca's $2 Billion Investment in Summit Therapeutics Seen as 'Win-Win,' UBS Says

Summit Therapeutics: Stronger Balance Sheet Helps, But It Does Not De-Risk Ivonescimab

AstraZeneca Stock Slips as $2 Billion Summit Stake Deepens Oncology

Summit Stock Jumps 17% on $2 Billion AstraZeneca Investment

Summit Shares Jump on $2B Strategic Investment From AstraZeneca

Also Discussed

Summit Therapeutics Inc.

Company Information

Location

A $2 Billion Reason Why AstraZeneca Stock Is Down Today

AstraZeneca's $2 Billion Investment in Summit Therapeutics Seen as 'Win-Win,' UBS Says

Summit Therapeutics: Stronger Balance Sheet Helps, But It Does Not De-Risk Ivonescimab

AstraZeneca Stock Slips as $2 Billion Summit Stake Deepens Oncology

Summit Stock Jumps 17% on $2 Billion AstraZeneca Investment

Summit Shares Jump on $2B Strategic Investment From AstraZeneca

Also Discussed

Social

Sep 29

Bullish· Sep 29

Bearish· Sep 29

Announcements· Sep 29

Technical Analysis· Sep 13

Regulars· Sep 29

Newcomers· Sep 29